Most positive tests for RSV so far this season in Canada have been among the youngest, federal data suggests. And while ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, accord ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...

Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...

Kling Biotherapeutics ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, ...

In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.